Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (286)	3/18/1999 6:27:00 PM
From: JOEBT1	Respond to of 3158

Peter--I agree with you there will be more buyouts of biotechs but also continued partnering of big pharma on early stage products with biotechs. The most important criterion for a buyout of a biotech would be near term profitability or present profitability coupled with drugs that have a significant market (> 500M). Some examples that meet this criterion are Centocor, Immunex, Immunomedics, Scios, CORR? etc. Some that are close (less than 2 years) are Ligand, GLIA, PDLI, Sepracor, etc. Another important criterion is that the biotech has retained significant rights to their products. Market cap is also important. Poor candidates IMO are early stage third tier biotechs--Big or medium pharma will partner with these companies rather than buy them. Examples are BTRN, TTP,OSIP,SIBI etc.